American Society of Clinical Oncology Annual Meeting (ASCO) | Conference

Meric-Bernstam, MD, Discusses Pertuzumab Plus Trastuzumab Use Across HER2-Positive Solid Tumors
August 05, 2021

CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.

Prior Therapy Does Not Influence Selpercatinib Efficacy in RET+ Medullary Thyroid Cancer
June 08, 2021

Responses to selpercatinib in patients with pretreated medullary thyroid cancer were noted irrespective of therapy regimens received in prior lines, according to data from the 2021 ASCO Annual Meeting.

Larotrectinib Is Efficacious and Tolerable in NTRK-Fusion Positive CNS Tumors
June 07, 2021

Data from 2 clinical trials proved that larotrectinib is efficacious and safe in treating adults and children with NTRK fusion-positive central nervous system cancers.